Effects of Lizhong Tang on gastrointestinal motility in mice

• Published in: World journal of gastroenterology : WJG Vol. 22; no. 34; pp. 7778 - 7786
• Main Authors: Lee, Min Cheol, Ha, Wooram, Park, Jinhyeong, Kim, Junghoon, Jung, Yunjin, Kim, Byung Joo
• Format: Journal Article
• Language: English
• Published: United States Baishideng Publishing Group Inc 14.09.2016
• Subjects: Animals; Basic Study; Chromatography; Cisplatin - administration & dosage; disorders;Motility;Intestinal; Drugs, Chinese Herbal - therapeutic use; emptying; Gastric Emptying; Gastrointestinal Motility - drug effects; Gastrointestinal Transit; Lizhong; Loperamide - administration & dosage; Male; Mice; Mice, Inbred ICR; Plant Extracts - chemistry; rate;Gastric; Tang;Gastrointestinal; transit; Gastric emptying; Gastrointestinal disorders; Motility; Lizhong Tang; Intestinal transit rate
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v22.i34.7778

AIM To investigate the effects of Lizhong Tang,a traditional Chinese medicine formula,on gastrointestinal motility in mice.METHODS The in vivo effects of Lizhong Tang on GI motility were investigated by measuring the intestinal transit rates(ITRs) and gastric emptying(GE) values in normal mice and in mice with experimentally induced GI motility dysfunction(GMD).RESULTS In normal ICR mice,the ITR and GE values were significantly and dose-dependently increased by Lizhong Tang(ITR values: 54.4% ± 1.9% vs 65.2% ± 1.8%,P < 0.01 with 0.1 g/kg Lizhong Tang and 54.4% ± 1.9% vs 83.8% ± 1.9%,P < 0.01 with 1 g/kg Lizhong Tang; GE values: 60.7% ± 1.9% vs 66.8% ± 2.1%,P < 0.05 with 0.1 g/kg Lizhong Tang and 60.7% ± 1.9% vs 72.5% ± 1.7%,P < 0.01 with 1 g/kg Lizhong Tang). The ITRs of the GMD mice were significantly reduced compared with those of the normal mice,which were significantly and dose-dependently reversed by Lizhong Tang. Additionally,in loperamide- and cisplatin-induced models of GE delay,Lizhong Tang administration reversed the GE deficits.CONCLUSION These results suggest that Lizhong Tang may be a novel candidate for development as a prokinetic treatment for the GI tract.